Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,034 across all filing types
Latest filing 2025-08-14 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from Glenmark Pharmaceuticals dated August 14, 2025, presenting financial results for the first quarter ended June 30, 2025 (Q1FY26). It includes comprehensive financial data such as revenue figures by region, EBITDA, adjusted PAT, and growth percentages. It also contains management commentary on the results, operational reviews, product launches, and strategic updates. The document explicitly states it is a "Press Release and Management Discussion & Analysis" for the quarter ended June 30, 2025. The length is substantial (15,000 characters), and it contains actual financial data and analysis, not just a brief announcement or a link to a report. This fits the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year, containing substantive financial data and analysis. Therefore, the correct classification is IR with high confidence.
2025-08-14 English
Outcome of Board Meeting
Regulatory Filings
2025-08-14 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is a formal letter from Glenmark Pharmaceuticals Limited addressed to stock exchanges, informing them about an upcoming earnings call scheduled for August 18, 2025. It includes details such as date, time, dial-in numbers, and contact information for clarifications. The document does not contain any financial data or results itself, but rather serves as an announcement or invitation to the earnings call. The length is short (1978 characters), and it explicitly states the call will happen in the future and that the recording will be available later. Therefore, this document is best classified as a Call Transcript (CT) announcement or invitation, but since it is only an invitation and not the transcript itself, it fits the category of Regulatory Filings (RNS) as a general announcement. However, given the classification options, the closest and most appropriate category is Call Transcript (CT) because it relates directly to the earnings call event. Confidence is high due to clear keywords like 'Earnings Call' and detailed call logistics.
2025-08-08 English
General Updates
Legal Proceedings Report Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, which pertains to ongoing legal proceedings involving the company and its subsidiary. It details a settlement agreement related to antitrust and consumer protection lawsuits. The document is addressed to stock exchanges and is informational in nature, providing an update on legal matters. It does not contain financial statements, audit results, or detailed management discussion, nor is it a transcript or presentation. It is not a full legal proceeding report but an announcement of legal proceedings and settlement. Therefore, it fits best under the category of Legal Proceedings Report (LTR). The document length is 3376 characters, which is sufficient for a detailed announcement but not a full report. Hence, the classification is LTR with high confidence.
2025-08-06 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-08-04 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a notification addressed to stock exchanges about an upcoming Board Meeting scheduled for August 14, 2025, to consider and approve the unaudited financial results for the first quarter ended June 30, 2025. It also mentions the closure of the trading window for insider trading compliance. The document is short (1935 characters) and serves as an announcement of the meeting and the forthcoming financial results, not the financial report itself. Therefore, it is not an Interim/Quarterly Report (IR) but rather a Regulatory Filing (RNS) as it is a general regulatory announcement about the board meeting and financial results approval date.
2025-08-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.